Lutathera® Oncology: Solid Tumors Registration 2024 Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3 tumors (GEP-NET 1L G3) Supplementary Indication PrintPDF